Aster DM Healthcare Limited has informed the Exchange about Investor Presentation
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aster DM Healthcare reported strong FY25 results with revenue up 12% YoY to Rs 4,138 crore and operating EBITDA up 30% to Rs 806 crore. Operating EBITDA margin expanded by 270 basis points to 19.5%, driven by operational efficiencies, better leverage, and improved payor mix. Normalised profit after tax rose 49% to Rs 357 crore, and the company turned net cash positive with cash and investments of Rs 1,381 crore versus Rs 114 crore a year ago. The share swap for the Quality Care (QCIL) merger has been completed, with CCI approval received and merger expected to close in Q4 FY26; on a combined basis, FY25 revenue would be Rs 8,105 crore with EBITDA of Rs 1,661 crore at a 20.5% margin. Management has outlined plans to add 2,100+ beds to reach approximately 7,300 beds, with key clusters in Karnataka & Maharashtra and Andhra & Telangana delivering 28% and 15% revenue growth respectively.
Strong margin expansion, net cash position, and the Quality Care merger progressing on schedule are positive signals for shareholders, though Kerala cluster revenue declined 4% in Q4 due to lower international footfall and festivities. The combined entity's scale and identified synergies of 10-15% of FY24 proforma EBITDA could support further rerating.